Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study

    January 2026 in “ Yonsei Medical Journal ”
    Minh-Ha Nguyen, Juyeon Ko, Jaelim Cho
    Studysummary Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on eymj.org →
    Discuss this study in the Community →

    Research cited in this study 8

    1. Risk of Poor Glycemic Control in Tamsulosin Versus Finasteride Users with Type 2 Diabetes Mellitus Heliyon · 2025
    2. Risk of Depression After 5 Alpha Reductase Inhibitor Medication: Meta-Analysis The World Journal of Men's Health · 2019
    3. Incidence of Type 2 Diabetes Mellitus in Men Receiving Steroid 5α-Reductase Inhibitors: Population-Based Cohort Study BMJ. British medical journal · 2019
    4. Sexual Dysfunction in Subjects Treated with Inhibitors of 5α-Reductase for Benign Prostatic Hyperplasia: A Comprehensive Review and Meta-Analysis International Journal of Andrology · 2017
    5. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor ˜The œJournal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism · 2004
    6. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia The New England Journal of Medicine · 1998
    7. The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia The New England Journal of Medicine · 1996
    8. The Effect of Finasteride in Men with Benign Prostatic Hyperplasia The New England Journal of Medicine · 1992